TME Pharma
TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Our clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned.
|
LATEST DATA IN THE GLIOBLASTOMA STUDY ASCO 2022 Poster: Full top-line results from NOX-A12 Phase 1/2 GLORIA trial in GBM presented at the 2022 ASCO Annual Meeting |
Press ReleaseBerlin, Germany 2022, August 03 08:00 a.m. TME Pharma announces enrollment of first patient in pembrolizumab expansion arm of NOX-A12 GLORIA Phase 1/2 brain cancer clinical trial 2022, July 27 07:00 p.m. TME Pharma announces completion of share consolidation 2022, July 15 06:00 p.m. TME Pharma announces €3.24 million financing under agreement with Atlas |
EventsESMO Congress 2022
Aram Mangasarian, Avital Barak, Dirk Eulberg BIO-Europe
Aram Mangasarian, Ewelina Staniuk |